Ben combines a Ph.D. in Chemistry from Columbia University with nearly fifteen years of IP practice at firms including Quinn Emanuel, WilmerHale, Loeb & Loeb, and Weiss & Arons, where he served as Partner. His scientific training allows him to evaluate patent claims at the molecular and algorithmic level without relying on outside technical experts—reading specifications, assessing enablement, identifying prior art vulnerabilities, and constructing claim charts with the precision of a bench scientist and the judgment of a seasoned trial lawyer. That dual fluency makes him the person in the room who can tell you not just whether a patent exists, but whether it is worth anything.

His practice spans three interconnected disciplines. In IP transactions and brokerage, Ben structures patent acquisitions, portfolio divestitures, and strategic licensing campaigns that unlock value for companies at every stage—from pre-revenue startups seeking to de-risk a product launch to mature enterprises monetizing dormant assets. He conducts IP due diligence for M&A, venture financings, and PE platform investments, identifying hidden liabilities and overlooked value that directly influence deal terms and valuations. In technology commercialization, he guides innovators from lab bench to market entry, building freedom-to-operate clearance into the product development timeline and designing patent portfolios that protect competitive moats while supporting licensing revenue. In enforcement and litigation, he has represented clients in high-stakes patent disputes in federal courts, the Patent Trial and Appeal Board, and the Trademark Trial and Appeal Board, including pharmaceutical patent litigation involving blockbuster drugs such as Lialda, Vyvanse, Intuniv, Oxtellar XR, Pomalyst, Revlimid, and Cabometyx, as well as matters involving biological drugs and vaccines.

Ben’s approach to IP is defined by a single principle: intellectual property that is not connected to business strategy is an expense; intellectual property that is connected to business strategy is a weapon. He helps clients understand which patents in a portfolio actually cover revenue-generating products, which create barriers to competitive entry, which can be asserted or licensed for monetization, and which are candidates for abandonment or sale. He brings this same discipline to counseling companies on the IP of others—evaluating competitor patent filings as business intelligence, identifying assertion risks before they become litigation, and designing clearance strategies that let clients move faster, not slower.

His industry experience spans pharmaceuticals, biotechnology, medical devices, chemicals, AI and machine learning, blockchain and fintech, and consumer technology. He is admitted to practice in Florida, New York, and New Jersey, and is registered to practice before the United States Patent and Trademark Office. He holds his J.D. from Fordham University School of Law and his Ph.D. in Chemistry from Columbia University. He has been recognized as a Rising Star in Intellectual Property by Super Lawyers (2023, 2025) and has guest-lectured on IP strategy at several institutions.